FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

HERNEXEOS product image Product image This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) ...
Gut

Parental obesity and risk of metabolic dysfunction associated steatotic liver disease in adult offspring: UK birth cohort study

Background Metabolic dysfunction associated steatotic liver disease (MASLD), the most common chronic liver disease globally, may originate early in life. While maternal obesity is linked to offspring ...

Boehringer Ingelheim Limited: FDA approves HERNEXEOS, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...
BMJ Global Health

Forty years later: adult health and non-communicable disease following the 1984–1985 Great Ethiopian Famine – a retrospective cohort study

Background As the threat of child malnutrition increases, the focus remains mostly on short-term consequences. Long-term ...